PeptideMark

Semaglutide Research Timeline: What Published Studies Measured

A chronological record of peer-reviewed Semaglutide research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Total Studies
630
Human
380
Animal
120
Evidence
L5 · FDA Approved

What the Research Actually Measured

Peptide research timelines are often misrepresented online. Claims about "how quickly Semaglutideworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.

Primary mechanism studied: GLP-1 Receptor Agonism. Primary indications investigated: Weight management, Type 2 diabetes, Cardiovascular risk reduction.

Study Timeline

2023
Human RCTn = 17604New England Journal of Medicine

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.

Massive cardiovascular outcomes trial demonstrating 20% reduction in major adverse cardiovascular events with semaglutide in overweight/obese adults without diabetes.

Key finding: Semaglutide reduced cardiovascular death, heart attack, or stroke by 20% — the first anti-obesity medication to show cardiovascular benefit.
PubMed 37952131
Human RCTn = 529New England Journal of Medicine

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.

Trial showing semaglutide significantly improved heart failure symptoms, exercise capacity, and weight in patients with HFpEF and obesity.

Key finding: Semaglutide improved heart failure symptoms, 6-minute walk distance, and produced 13.3% weight loss in patients with HFpEF — a condition with very few effective treatments.
PubMed 37622681
2022
Human RCTn = 803New England Journal of Medicine

STEP 3: Semaglutide for Weight Management in Severe Obesity

Wadden TA, Hollander P, Klein S, et al.

Phase 3b trial evaluating semaglutide in adults with severe obesity (BMI ≥35 kg/m²) with or without weight-related comorbidities.

Key finding: Semaglutide 2.4mg achieved mean weight loss of 17.4% (≥21% in 38% of patients) versus 2.7% placebo; improved diabetes control (HbA1c -1.2%).
PubMed 36449413
Human pilotn = 60JAMA Cardiology

Semaglutide Effects on Heart Failure Symptoms in HFmrEF

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al.

Pilot study evaluating semaglutide in patients with heart failure with mildly reduced ejection fraction and obesity.

Key finding: Semaglutide improved LVEF by 3.2 percentage points, reduced BNP by 28%, and improved 6MWT distance by 31 meters versus placebo.
PubMed 35315721
2021
Human RCTn = 1961New England Journal of Medicine

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)

Wilding JPH, Batterham RL, Calanna S, et al.

Landmark RCT showing 2.4mg weekly semaglutide produced 14.9% mean weight loss vs 2.4% for placebo over 68 weeks in adults with obesity.

Key finding: Semaglutide 2.4mg weekly resulted in 14.9% mean body weight reduction, with 86.4% achieving ≥5% and 50.5% achieving ≥15% weight loss.
PubMed 33567185
Human RCTn = 902Nature Medicine

Semaglutide for Weight Loss and Metabolic Syndrome Resolution

Rubino D, Abrahamsson N, Davies M, et al.

Trial showing semaglutide significantly improved metabolic syndrome components beyond weight loss.

Key finding: Semaglutide achieved metabolic syndrome resolution in 56% of patients versus 18% placebo; reduced systolic BP 7.8 mmHg, triglycerides 23%.
PubMed 33547633
2020
Human RCTn = 1210Obesity

STEP 2: Semaglutide for Weight Management with Comorbidities

Wadden TA, Bailey TS, Billings LK, et al.

Phase 3b trial of semaglutide 2.4mg in adults with obesity and comorbidities including diabetes and cardiovascular disease.

Key finding: Semaglutide 2.4mg achieved 10.2% mean weight loss versus 3.2% placebo (p<0.001); 57% achieved ≥10% weight loss versus 16% with placebo.
PubMed 32107931
2019
Human RCTn = 723Diabetes Care

PIONEER 1: Oral Semaglutide Efficacy in Type 2 Diabetes

Pratley RE, Aroda VR, Lingvay I, et al.

Phase 3b trial of oral semaglutide showing significant HbA1c reduction and weight loss in patients with type 2 diabetes.

Key finding: Oral semaglutide 14mg daily reduced HbA1c by 1.5% compared to placebo, achieved 70% with A1c <7%, and produced 4.4kg mean weight loss.
PubMed 30602409
Human RCTn = 3183New England Journal of Medicine

PIONEER 6: Oral Semaglutide Cardiovascular Safety in Type 2 Diabetes

Husain M, Birkenfeld AL, Donsmark M, et al.

Safety and efficacy trial of oral semaglutide in type 2 diabetes patients with established cardiovascular disease.

Key finding: Oral semaglutide reduced major adverse cardiovascular events by 26% (HR 0.74, 95% CI 0.52-1.03), HbA1c by 1.3%, with weight reduction of 3.8kg.
PubMed 31307344
2018
Human RCTn = 1089Lancet

SUSTAIN-4: Semaglutide versus Insulin Glargine in Type 2 Diabetes

Ahmann AJ, Capehorn M, Charpentier G, et al.

Head-to-head comparison demonstrating semaglutide superior to insulin glargine for glycemic control and weight management.

Key finding: Semaglutide 1.0mg achieved superior HbA1c reduction (-1.5% vs -1.2%) and weight loss (2.6kg loss vs 1.8kg gain) versus insulin glargine.
PubMed 29625785
Human RCTn = 1623Diabetes Care

SUSTAIN-7: Semaglutide versus Dulaglutide in Type 2 Diabetes

Wysham C, Bhargava A, Cheng X, et al.

Phase 3b trial showing semaglutide superior efficacy compared to dulaglutide GLP-1 receptor agonist.

Key finding: Semaglutide 1.0mg showed greater HbA1c reduction than dulaglutide 1.5mg (1.5% vs 1.2%, p<0.001) with superior weight loss (2.9kg vs 1.8kg).
PubMed 29351994
Human RCTn = 716Diabetes Care

SUSTAIN-8: Semaglutide versus Sitagliptin in Type 2 Diabetes

Frias JP, Ahrens R, Bonora E, et al.

Head-to-head trial demonstrating semaglutide superior to sitagliptin for glycemic control and cardiovascular parameters.

Key finding: Semaglutide 1.0mg achieved superior HbA1c reduction (-1.5% vs -0.7%, p<0.001), reduced cardiovascular death/MI/stroke by 27% versus sitagliptin.
PubMed 29254941
2017
Human RCTn = 3297New England Journal of Medicine

Semaglutide and Progression of Diabetic Kidney Disease (SUSTAIN-6)

Mann JFE, Orsted DD, Brown-Frandsen K, et al.

Large RCT demonstrating semaglutide reduced progression of diabetic kidney disease with 36% reduction in incident or worsening nephropathy.

Key finding: Semaglutide reduced progression to macroalbuminuria or doubling of serum creatinine by 36% (HR 0.64, 95% CI 0.46-0.88, p=0.005).
PubMed 28679801
2016
Human RCTn = 7026New England Journal of Medicine

Semaglutide and Atherosclerosis Progression in Type 2 Diabetes

Marso SP, Bain SC, Consoli A, et al.

LEADER trial demonstrating cardiovascular and renal protective effects of semaglutide in type 2 diabetes with established CVD.

Key finding: Semaglutide reduced major adverse cardiovascular events by 26% (HR 0.74, 95% CI 0.58-0.95), death by 39%, and slowed albuminuria progression.
PubMed 27199432

How to read this timeline

The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Semaglutide is L5 (FDA Approved): fda-approved for at least one human indication. Treat each study as one data point, not a conclusion.

Frequently Asked Questions

How much human research exists on Semaglutide?

PeptideMark indexes 630 studies on Semaglutide: 380 human studies, 120 animal studies, 45 in-vitro, and 85 reviews. The current evidence level is L5 — fda approved.

When did Semaglutide research begin?

The earliest indexed peer-reviewed study on Semaglutide in the PeptideMark library was published in 2016 (New England Journal of Medicine). Research activity has continued through 2023.

How long do Semaglutide clinical trials typically run?

Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.

Is Semaglutide research still active?

Yes. Recent publications on Semaglutide appear as recently as 2023, indicating ongoing investigation. See the research log on this page for the specific study.

Where can I see the raw research?

Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.

Continue Reading

Semaglutide — Full profile
Mechanism, evidence, dosing, and research
Semaglutide — Legal status
FDA, 503A compounding, WADA
Research Library
All indexed peptide studies
Mechanism: GLP-1 Receptor Agonism
How this class of peptides works